Novo Nordisk A/S $NVO Shares Acquired by Parallel Advisors LLC

Parallel Advisors LLC raised its position in Novo Nordisk A/S (NYSE:NVO) by 27.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 55,856 shares of the company’s stock after purchasing an additional 12,138 shares during the quarter. Parallel Advisors LLC’s holdings in Novo Nordisk A/S were worth $2,053,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Godfrey Financial Associates Inc. purchased a new position in shares of Novo Nordisk A/S during the 4th quarter worth approximately $25,000. Scarborough Advisors LLC acquired a new position in Novo Nordisk A/S during the 1st quarter worth $26,000. WealthCollab LLC increased its stake in shares of Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after buying an additional 260 shares during the period. Maseco LLP purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $29,000. Finally, Jackson Grant Investment Advisers Inc. acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at $29,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Up 3.1%

Shares of NYSE:NVO opened at $45.90 on Friday. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $64.16. The stock’s 50-day moving average price is $46.96 and its two-hundred day moving average price is $45.01. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The firm has a market cap of $204.96 billion, a price-to-earnings ratio of 11.22, a PEG ratio of 4.06 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The business had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. On average, research analysts forecast that Novo Nordisk A/S will post 3.39 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a dividend, which will be paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th will be paid a dividend of $0.5786 per share. The ex-dividend date is Monday, August 17th. This represents a yield of 254.0%. Novo Nordisk A/S’s dividend payout ratio is currently 42.79%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Nordea Equity Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Finally, Zacks Research cut shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Five investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Hold” and a consensus target price of $65.81.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Strong quarterly results and raised outlook: Novo Nordisk beat second-quarter revenue expectations by approximately 10% and adjusted EPS estimates by more than 20%. Revenue increased 7% year over year, operating profit rose 11%, and management lifted its 2026 sales and profit outlook for the second time this year. Novo Nordisk: The Market Has Lost Its Mind, Too Cheap To Ignore
• Positive Sentiment: Continued GLP-1 demand: International markets and obesity care continued to drive growth, while accelerating demand for the Wegovy pill supported the improved outlook. The company also retains substantial profitability and cash generation to fund research, development and shareholder returns. NVO Q2 Earnings Call Centers on Wegovy Pill and Outlook Lift
• Positive Sentiment: Patent enforcement win: A Dutch court ordered Ceban Ziekenhuisfarmacie to stop selling an infringing compounded semaglutide nasal spray, remove product listings and provide supply-chain information. The ruling could help protect Novo’s semaglutide franchise from unauthorized competition in the Netherlands. Novo Nordisk wins Dutch court injunction
• Neutral Sentiment: Novo declared a dividend of 0.5786 per share, payable August 25 to shareholders of record August 17. The reported 254% yield appears inconsistent with the stated dividend and should be treated cautiously pending confirmation. Novo Nordisk dividend and insider transactions announcement
• Negative Sentiment: Pipeline and competitive concerns remain the main overhang: Investors focused on weaker-than-expected Wegovy pill sales, a setback for the next-generation obesity treatment CagriSema, U.S. pricing pressure and the widening commercial lead of Eli Lilly’s GLP-1 portfolio. These issues overshadowed the earnings beat and guidance increase. The divide between Eli Lilly and Novo Nordisk is widening

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.